Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status

Molecular Carcinogenesis

Volumn 52, Issue SUPPL1, 2013, Pages 52-59

  Cen, Yu Ling ^a   Qi, Mei Ling ^a   Li, Hai Gang ^a   Su, Yi ^a   Chen, Li Juan ^a   Lin, Ying ^a   Chen, Wei Qing ^a   Xie, Xiao Ming ^b   Tang, Lu Ying ^a   Ren, Ze Fang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Breast cancer; Fibroblast growth factor 1; Fibroblast growth factor receptor 2; Polymorphism; RNA binding protein fox 1 homolog 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MEMBRANE PROTEIN; PROGESTERONE RECEPTOR; PROTEIN RBFOX2; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MARRIAGE; MENARCHE; PARITY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR VOLUME;

BREAST CANCER; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; POLYMORPHISM; RNA BINDING PROTEIN FOX-1 HOMOLOG 2;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 1; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRESSOR PROTEINS; RISK FACTORS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886288502     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21979     Document Type: Article

References (39)

1. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-1093.
2. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39:870-874.
3. Kawase T, Matsuo K, Suzuki T, et al. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan. Int J Cancer 2009; 125:1946-1952.
4. Liang J, Chen P, Hu Z, et al. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008; 29:2341-2346.
5. Boyarskikh UA, Zarubina NA, Biltueva JA, et al. Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. Eur J Hum Genet 2009; 17:1688-1691.
6. Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008; 6:e108.
7. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69:565-572.
8. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-149.
9. Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 2010; 10:116-129.
10. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281:15694-15700.
11. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007; 75:831-842.
12. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008; 6:435-445.
13. Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 2011; 30:603-611.
14. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15:740-746.
15. Baraniak AP, Chen JR, Garcia-Blanco MA. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Mol Cell Biol 2006; 26:1209-1222.
16. Sueta A, Ito H, Kawase T, et al. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat 2012; 132:711-721.
17. Wang P, Dai M, Xuan W, et al. SNP Function Portal: A web database for exploring the function implication of SNP alleles. Bioinformatics 2006; 22:e523-e529.
18. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008; 4:e1000054.
19. Reeves GK, Travis RC, Green J, et al. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA 2010; 304:426-434.
20. Su Y, Tang LY, Chen LJ, et al. Joint effects of febrile acute infection and an interferon-gamma polymorphism on breast cancer risk. PLoS ONE 2012; 7:e37275.
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145.
22. He JR, Tang LY, Yu DD, et al. Epstein-Barr virus and breast cancer: Serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett 2011; 309:128-136.
23. Rothman KJ. The estimation of synergy or antagonism. Am J Epidemiol 1976; 103:506-511.
24. Ren ZF, Liu WS, Qin HD, et al. Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong, China. Cancer Epidemiol 2010; 34:419-424.
25. Zhang L, Kharbanda S, Chen D, et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997; 15:2093-2108.
26. Zhang L, Kharbanda S, McLeskey SW, Kern FG. Overexpression of fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes. Cancer Res 1999; 59:5023-5029.
27. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008; 14:8000-8009.
28. Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2000; 18:573-580.
29. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66:273-280.
30. Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T. Expression of keratinocyte growth factor and its receptor in human breast cancer: Its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol 2004; 67:455-464.
31. Tamaru N, Hishikawa Y, Ejima K, et al. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 2004; 84:1460-1471.
32. Miki T, Bottaro DP, Fleming TP, et al. Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 1992; 89:246-250.
33. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-178.
34. Yoshimura N, Sano H, Hashiramoto A, et al. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 1998; 89:28-34.
35. Venables JP, Klinck R, Koh C, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16:670-676.
36. Lapuk A, Marr H, Jakkula L, et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 2010; 8:961-974.
37. Prudovsky I, Savion N, Zhan X, et al. Intact and functional fibroblast growth factor (FGF) receptor-1 trafficks near the nucleus in response to FGF-1. J Biol Chem 1994; 269:31720-31724.
38. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004; 6:240-245.
39. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13:1558-1568.